201286-99-9

Basic information

• Product Name: 6-Hydroxy-3-methylindazole
• Synonyms: 6-Hydroxy-3-methylindazole;3-Methylindazol-6-ol
• CAS NO: 201286-99-9
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16
• Mol File: 201286-99-9.mol

Chemical Properties

• Boiling Point: 366.002 °C at 760 mmHg
• Flash Point: 175.152 °C
• Appearance: /
• Density: 1.349 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.719
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 9.26±0.40(Predicted)
• CAS DataBase Reference: 6-Hydroxy-3-methylindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxy-3-methylindazole(201286-99-9)
• EPA Substance Registry System: 6-Hydroxy-3-methylindazole(201286-99-9)

Safety Data

• Hazardous Substances Data: 201286-99-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Hydroxy-3-methylindazole is used as an intermediate or active ingredient for the development of pharmaceutical products, due to its potential biological activity and chemical properties.
Used in Agricultural Applications:
6-Hydroxy-3-methylindazole is used as a component in agrochemicals, potentially for pest control or crop protection, leveraging its chemical properties to target specific pests or enhance crop growth.
Used in Research Purposes:
6-Hydroxy-3-methylindazole is used as a research compound in material science and biological studies, where its properties can be explored for new applications or to understand its interactions with other compounds and biological systems.

InChI:InChI=1/C8H8N2O/c1-5-7-3-2-6(11)4-8(7)10-9-5/h2-4,11H,1H3,(H,9,10)

Upstream product

• 79173-62-9 3-methyl-1H-indazol-6-amine 
• 6494-19-5 3-methyl-6-nitro-1H-indazole 
• 7746-29-4 6-methoxy-3-methyl-1H-indazole 
• 7732-18-5 water 
• 98619-07-9 1-(2-fluoro-4-hydroxyphenyl)ethanone 
• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 
• 519158-44-2 1-benzyl-3-methyl-1H-indazol-6-ol 

Downstream Products

• 1221179-02-7 C₂₄H₂₆N₂OSi 
• 1221179-36-7 tert-butyl 6-(2-(dibenzylamino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-37-8 tert-butyl 6-(2-(benzylamino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-29-8 tert-butyl (R)-6-[2-[N-((2-(3-aminophenyl)-2-((triethylsilyl)oxy)ethyl)-N-(tert-butoxycarbonyl)amino)]ethoxy]-3-methyl-1H-indazole-1-carboxylate 
• 1221179-44-7 (R)-tert-butyl 6-(2-((2-(3-amino-4-chlorophenyl)-2-(triethylsilyloxy)ethyl)(tert-butoxycarbonyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-38-9 (R)-tert-butyl 6-(2-(benzyl(2-(4-fluoro-3-nitrophenyl)-2-hydroxyethyl)amino)ethoxy)-3-methyl indazole-1-carboxylate 
• 1221179-41-4 (R)-tert-butyl 6-(2-(benzyl(2-(4-chloro-3-nitrophenyl)-2-hydroxyethyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-42-5 (R)-tert-butyl 6-(2-((2-(3-amino-4-chlorophenyl)-2-hydroxyethyl)(benzyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-43-6 (R)-tert-butyl 6-(2-((2-(3-amino-4-chlorophenyl)-2-hydroxyethyl)(tert-butoxycarbonyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-03-8 C₂₉H₃₄N₂O₃Si 
• 1283126-28-2 (R)-tert-butyl 6-(2-((2-(3-(3-aminophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)(tert-butoxycarbonyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1283126-30-6 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(3-nitrophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1283126-47-5 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(4-chloro-3-nitrophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1283128-39-1 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(2-fluorophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-methylindazole-1-carboyxlate 

Relevant articles and documents

Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human β3-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant β3-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the α1A-AR (EC50 = 219 nM, selectivity: α1A/β3 = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for β3-AR agonistic activity versus α1A-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent β3-AR agonistic activity (EC50 = 13 nM) and high selectivity (α1A/β3 = >769-fold). Compound 11 was also inactive toward β1 and β2-ARs and showed dose dependent β3-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.

INDAZOLE ANALOGUE

[Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.

INDAZOLE COMPOUNDS

Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

BICYCLIC COMPOUND

Compounds of the general formula (I): or a salt thereof, wherein R1 is a hydrogen atom or the like; R2 is NHSO2R3 or the like; R3 is a (C1-C6)alkyl group or the like; R5 is a hydrogen atom or the like; R6 and R7 may be the same or different and each independently represents a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z1 to Z6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R5 is other than a hydrogen atom.

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.